Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07174687 · ClinicalTrials.gov registry record · Phase 2
SGLT2 Inhibitors in Geographic Atrophy
A Phase 2 study of Eye Diseases and Geographic Atrophy, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT07174687: Recruiting Phase 2 study of Eye Diseases and Geographic Atrophy, sponsored by Washington University School of Medicine.
NCT07174687 is a Phase 2 study of Eye Diseases and Geographic Atrophy that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 70 participants, below the 741,300-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07174687, a Phase 2 study of Eye Diseases and Geographic Atrophy, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
AMD is a leading cause of blindness in individuals over 50 years old, with dry AMD being the most common form. Geographic atrophy (GA) is an advanced stage of dry AMD characterized by progressive retinal cell degeneration. The primary objectives of the study are to assess the safety, tolerability, and evidence of activity of SGLT2 inhibitors in subjects with Geographic Atrophy associated with AMD.
Primary Outcome
The square root GA lesion size (i.e. transformed area of GA) was measured by FAF photographs at baseline and 12 months. Baseline is defined as the last available, non-missing observation prior to first study drug administration.
Conditions Studied
Interventions
- DRUG Dapagliflozin
- OTHER Matching Placebo
Study Locations (1)
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-12-02 |
| Est. Completion | 2028-06 |
| Phase | Phase 2 |
What NCT07174687 shows while recruiting
NCT07174687 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 741,300-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower).
The record links to 5 conditions, with Eye Diseases appearing as the primary indexed condition, and to 2 interventions - of which Dapagliflozin is the first listed.
NCT07174687 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT07174687 about?
NCT07174687 is a clinical study titled "SGLT2 Inhibitors in Geographic Atrophy". AMD is a leading cause of blindness in individuals over 50 years old, with dry AMD being the most common form. Geographic atrophy (GA) is an advanced stage of dry AMD characterized by progressive retinal cell degeneration. The primary objectives of the study are to assess the safety, tolerability, a...
What is the current status of trial NCT07174687?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2025-12-02. Estimated completion is 2028-06.
What conditions does trial NCT07174687 study?
This clinical trial studies the following conditions: Eye Diseases, Geographic Atrophy, Retinal Degeneration, Retinal Diseases, Pathological Conditions, Anatomical.
What interventions are being tested in trial NCT07174687?
The interventions under investigation include: Dapagliflozin (DRUG), Matching Placebo (OTHER).
Who is sponsoring clinical trial NCT07174687?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07174687 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eye Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07174687's enrollment target sits among peer trials
70 15th of 27 higher than 12 of 27 other Eye Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Eye Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
RECRUITING · Phase 2
-
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
COMPLETED · Phase 2
-
Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
COMPLETED · Phase 2
-
Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI